INTRODUCTION: Pharmacists are uniquely positioned within the community to provide smoking cessation counseling to their patients. However, pharmacists experience significant barriers to providing counseling, including limited time, reimbursement, and training in counseling techniques. We tested a computer-driven software system, "Exper_Quit" (EQ), that provided individually tailored interventions to patients who smoke and matching tailored reports for pharmacists to help guide cessation counseling. METHODS: A two-phase design was used to recruit an observation-only group (OBS; n = 100), followed by participants (n = 200) randomly assigned to receive either EQ-assisted pharmacist counseling or EQ plus 8 weeks of nicotine transdermal patch (EQ+). Both treatment groups were scheduled to receive two follow-up counseling calls from pharmacists. RESULTS: Most participants in the EQ and EQ+ groups reported receiving counseling from a pharmacist, including follow-up calls, while none of the OBS participants reported speaking with the pharmacist about cessation. At 6 months, fewer OBS participants reported a quit attempt (42%) compared with EQ (76%) or EQ+ (65%) participants (p < .02). At 6 months, 7-day point-prevalence abstinence was 28% and 15% among the EQ+ and EQ groups, respectively, compared with 8% among OBS participants (p < .01), and EQ+ participants were twice as likely to be quit than were EQ participants (p < .01). DISCUSSION: A tailored software system can facilitate the delivery of smoking cessation counseling to pharmacy patients. Results suggest that EQ was successful in increasing (a) the delivery of cessation counseling, (b) quit attempts, and (c) quit rates. Pharmacists can play an important role in the effective delivery of smoking cessation counseling.
RCT Entities:
INTRODUCTION: Pharmacists are uniquely positioned within the community to provide smoking cessation counseling to their patients. However, pharmacists experience significant barriers to providing counseling, including limited time, reimbursement, and training in counseling techniques. We tested a computer-driven software system, "Exper_Quit" (EQ), that provided individually tailored interventions to patients who smoke and matching tailored reports for pharmacists to help guide cessation counseling. METHODS: A two-phase design was used to recruit an observation-only group (OBS; n = 100), followed by participants (n = 200) randomly assigned to receive either EQ-assisted pharmacist counseling or EQ plus 8 weeks of nicotine transdermal patch (EQ+). Both treatment groups were scheduled to receive two follow-up counseling calls from pharmacists. RESULTS: Most participants in the EQ and EQ+ groups reported receiving counseling from a pharmacist, including follow-up calls, while none of the OBS participants reported speaking with the pharmacist about cessation. At 6 months, fewer OBS participants reported a quit attempt (42%) compared with EQ (76%) or EQ+ (65%) participants (p < .02). At 6 months, 7-day point-prevalence abstinence was 28% and 15% among the EQ+ and EQ groups, respectively, compared with 8% among OBS participants (p < .01), and EQ+participants were twice as likely to be quit than were EQparticipants (p < .01). DISCUSSION: A tailored software system can facilitate the delivery of smoking cessation counseling to pharmacy patients. Results suggest that EQ was successful in increasing (a) the delivery of cessation counseling, (b) quit attempts, and (c) quit rates. Pharmacists can play an important role in the effective delivery of smoking cessation counseling.
Authors: Victor J Strecher; Jennifer B McClure; Gwen L Alexander; Bibhas Chakraborty; Vijay N Nair; Janine M Konkel; Sarah M Greene; Linda M Collins; Carola C Carlier; Cheryl J Wiese; Roderick J Little; Cynthia S Pomerleau; Ovide F Pomerleau Journal: Am J Prev Med Date: 2008-05 Impact factor: 5.043
Authors: Karen Suchanek Hudmon; Kimberly Bardel; Lisa A Kroon; Christine M Fenlon; Robin L Corelli Journal: Nicotine Tob Res Date: 2005-04 Impact factor: 4.244
Authors: Thomas K Houston; Joshua S Richman; Midge N Ray; Jeroan J Allison; Gregg H Gilbert; Richard M Shewchuk; Connie L Kohler; Catarina I Kiefe Journal: J Med Internet Res Date: 2008-11-04 Impact factor: 5.428
Authors: Lindsay Wong; Andrea M Burden; Yan Yun Liu; Mina Tadrous; Nedzad Pojskic; Lisa Dolovich; Andrew Calzavara; Suzanne M Cadarette Journal: Can Pharm J (Ott) Date: 2015-01
Authors: Nervana Elkhadragy; Robin L Corelli; Alissa L Russ; Margie E Snyder; Mercedes Clabaugh; Karen Suchanek Hudmon Journal: Res Social Adm Pharm Date: 2019-01-09
Authors: José S Marcano Belisario; Michelle N Bruggeling; Laura H Gunn; Serena Brusamento; Josip Car Journal: Cochrane Database Syst Rev Date: 2012-12-12
Authors: Liz Steed; Ratna Sohanpal; Adam Todd; Vichithranie W Madurasinghe; Carol Rivas; Elizabeth A Edwards; Carolyn D Summerbell; Stephanie Jc Taylor; R T Walton Journal: Cochrane Database Syst Rev Date: 2019-12-06
Authors: Dennis Thomas; Michael J Abramson; Billie Bonevski; Simone Taylor; Susan Poole; Gregory R Weeks; Michael J Dooley; Johnson George Journal: Trials Date: 2013-05-21 Impact factor: 2.279